Gaudium IVF & Women Health IPO Review: Key Details, Company Overview, Industry Context

The Gaudium IVF & Women Health IPO opened for subscription on February 20, 2026 and closed on February 24, 2026. The issue attracted attention amid growing investor interest in India’s fertility and women’s healthcare sector.

The basis of allotment was likely finalised on February 25, 2026, and the shares are expected to list on both BSE and NSE on February 27, 2026, subject to final approvals.

IPO Key Details

IPO Opening Date: February 20, 2026

IPO Closing Date: February 24, 2026

Allotment Date: February 25, 2026 (expected)

Listing Date: February 27, 2026 (expected)

Listing Exchanges: BSE and NSE

Price Band: ₹75 to ₹79 per equity share

Lot Size: 189 shares

Minimum Investment (Retail): ₹14,931 at upper band

Retail maximum, S-HNI and B-HNI investment limits vary depending on the number of lots applied.

Book Running Lead Manager: Smart Horizon Capital Advisors

Registrar: Bigshare Services Pvt. Ltd.

Company Overview

Gaudium IVF & Women Health Limited is a fertility and women’s healthcare services provider offering In Vitro Fertilisation (IVF), advanced Assisted Reproductive Technologies (ART), and related clinical care services.

The company operates a hub-and-spoke model, comprising:

7 full-service IVF hubs

28 spokes across India

This model enables centralized expertise and cost efficiency at hub centres, while spokes increase patient accessibility across geographies.

Key Services Offered

In Vitro Fertilisation (IVF)

Intracytoplasmic Sperm Injection (ICSI)

Intrauterine Insemination (IUI)

Ovulation induction

Male infertility treatments

Fertility preservation procedures

Comprehensive women’s healthcare services

The company also serves international patients from the UK, USA, Canada, Kenya, South Africa, and Oman, benefiting from India’s growing medical tourism ecosystem.

Industry Context: Fertility & ART Sector Growth

India’s fertility services and ART sector is witnessing strong structural growth due to:

Increasing infertility rates

Delayed marriages and rising maternal age

Changing lifestyle patterns

Greater awareness about fertility treatments

Improved medical infrastructure

The Indian IVF market was valued at approximately USD 1.32 billion in 2024 and is projected to grow at a CAGR of around 13.1%, potentially reaching USD 4.54 billion by 2034.

Globally, the IVF market is also expanding steadily due to technological advancements and rising demand for assisted reproduction. Cities such as Delhi, Mumbai, and Bangalore are emerging as key IVF treatment hubs, supporting industry momentum.

Business Strengths

Expanding infertility patient base driven by demographic and lifestyle changes

Adoption of advanced reproductive technologies improving clinical outcomes

Scalable hub-and-spoke expansion model enabling capital-efficient growth

Integrated fertility and women’s healthcare services increasing patient lifetime value

Exposure to medical tourism and international patient inflow

These strengths position the company to benefit from long-term demand trends in fertility care.

The Gaudium IVF & Women Health IPO opened for subscription on February 20, 2026 and closed on February 24, 2026. The issue attracted attention amid growing investor interest in India’s fertility and women’s healthcare sector. The basis of allotment was likely finalised on February 25, 2026, and the shares are expected to list on both BSE and NSE on February 27, 2026, subject to final approvals.

IPO Key Details

IPO Opening Date: February 20, 2026 IPO Closing Date: February 24, 2026 Allotment Date: February 25, 2026 (expected) Listing Date: February 27, 2026 (expected) Listing Exchanges: BSE and NSE Price Band: ₹75 to ₹79 per equity share Lot Size: 189 shares Minimum Investment (Retail): ₹14,931 at upper band Retail maximum, S-HNI and B-HNI investment limits vary depending on the number of lots applied. Book Running Lead Manager: Smart Horizon Capital Advisors Registrar: Bigshare Services Pvt. Ltd.

Company Overview

Gaudium IVF & Women Health Limited is a fertility and women’s healthcare services provider offering In Vitro Fertilisation (IVF), advanced Assisted Reproductive Technologies (ART), and related clinical care services. The company operates a hub-and-spoke model, comprising: 7 full-service IVF hubs 28 spokes across India This model enables centralized expertise and cost efficiency at hub centres, while spokes increase patient accessibility across geographies.

Key Services Offered

In Vitro Fertilisation (IVF) Intracytoplasmic Sperm Injection (ICSI) Intrauterine Insemination (IUI) Ovulation induction Male infertility treatments Fertility preservation procedures Comprehensive women’s healthcare services The company also serves international patients from the UK, USA, Canada, Kenya, South Africa, and Oman, benefiting from India’s growing medical tourism ecosystem.

Industry Context: Fertility & ART Sector Growth

India’s fertility services and ART sector is witnessing strong structural growth due to: Increasing infertility rates Delayed marriages and rising maternal age Changing lifestyle patterns Greater awareness about fertility treatments Improved medical infrastructure The Indian IVF market was valued at approximately USD 1.32 billion in 2024 and is projected to grow at a CAGR of around 13.1%, potentially reaching USD 4.54 billion by 2034. Globally, the IVF market is also expanding steadily due to technological advancements and rising demand for assisted reproduction. Cities such as Delhi, Mumbai, and Bangalore are emerging as key IVF treatment hubs, supporting industry momentum.

Business Strengths

Expanding infertility patient base driven by demographic and lifestyle changes Adoption of advanced reproductive technologies improving clinical outcomes Scalable hub-and-spoke expansion model enabling capital-efficient growth Integrated fertility and women’s healthcare services increasing patient lifetime value Exposure to medical tourism and international patient inflow These strengths position the company to benefit from long-term demand trends in fertility care.